Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nanoliposomal irinotecan
- Development stage
- Approved
- Lead developer
- Ipsen
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous
01
Overview
Nanoliposomal irinotecan is a topoisomerase 1 inhibitor formulated as a nanoparticle liposome encapsulation of the active ingredient irinotecan. This formulation is designed to prolong circulation time and enhance delivery to tumor tissue compared to conventional (non-liposomal) irinotecan. The drug acts by inhibiting topoisomerase 1—leading to DNA damage and cell death in rapidly dividing cancer cells. Nanoliposomal encapsulation aims to maximize anti-tumor efficacy while minimizing systemic toxicity. It is primarily indicated for the treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC), both as first-line therapy in combination with oxaliplatin/fluorouracil/leucovorin (NALIRIFOX regimen) and after progression on gemcitabine-based therapy in combination with fluorouracil/leucovorin[1][2][3][4][5][7].
- Brand names
- Onivyde
- Other names
- irinotecan sucrosofateirinotecan liposome injectionliposomal irinotecanpegylated liposomal irinotecan hydrochloride trihydratenano-irinotecan
02
Targets
TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on nanoliposomal irinotecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nanoliposomal irinotecan.